A novel method for quantifying peripheral tissue amyloid load by using the radiolabeled amyloidophilic peptide, p5

References

• Lachmann HJ, Hawkins PN. Systemic amyloidosis. Curr Opin Pharmacol 2006;6:214–20
   PubMed Web of Science ®Google Scholar
• Pepys MB. Amyloidosis. Annu Rev Med 2006;57:223–41
   PubMed Web of Science ®Google Scholar
• Hawkins PN, Pepys MB. Imaging amyloidosis with radiolabelled SAP. Eur J Nucl Med 1995;22:595–9
   PubMedGoogle Scholar
• Hazenberg BP, van Rijswijk MH, Piers DA, Lub-de Hooge MN, Vellenga E, Haagsma EB, Hawkins PN, et al. Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. Am J Med 2006;119:355 e315–24
   Google Scholar
• Wall JS, Kennel SJ, Paulus MJ, Gleason S, Gregor J, Baba J, Schell M, et al. Quantitative High-Resolution Microradiographic Imaging of Amyloid Deposits in a Novel Murine Model of AA-Amyloidosis. Amyloid 2005;12:146–51
   Google Scholar
• Wall JS, Kennel SJ, Stuckey AC, Long MJ, Townsend DW, Smith GT, Wells KJ, et al. Radioimmunodetection of amyloid deposits in patients with AL amyloidosis. Blood 2010;116:2241–4
   PubMed Web of Science ®Google Scholar
• Wall JS, Richey T, Stuckey A, Donnell R, Macy S, Martin EB, Williams A, et al. In vivo molecular imaging of peripheral amyloidosis using heparin-binding peptides. Proc Natl Acad Sci U S A 2011;108:E586–94
   PubMed Web of Science ®Google Scholar
• Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med 1990;323:508–13
   PubMed Web of Science ®Google Scholar
• Townsend DW. Positron emission tomography/computed tomography. Semin Nucl Med 2008;38:152–66
   Google Scholar
• Townsend DW. Multimodality imaging of structure and function. Phys Med Biol 2008;53:R1–39
   PubMed Web of Science ®Google Scholar
• Lois C, Jakoby BW, Long MJ, Hubner KF, Barker DW, Casey ME, Conti M, et al. An assessment of the impact of incorporating time-of-flight information into clinical PET/CT imaging. J Nucl Med 2010;51:237–45
   PubMed Web of Science ®Google Scholar
• Lindahl B, Lindahl U. Amyloid-specific heparan sulfate from human liver and spleen. J Biol Chem 1997;272:26091–4
   PubMed Web of Science ®Google Scholar
• Smits NC, Kurup S, Rops AL, ten Dam GB, Massuger LF, Hafmans T, Turnbull JE, et al. The heparan sulfate motif (GlcNS6S-IdoA2S)3, common in heparin, has a strict topography and is involved in cell behavior and disease. J Biol Chem 2010;285:41143–51
   PubMed Web of Science ®Google Scholar
• Zhang X, Li JP. Heparan sulfate proteoglycans in amyloidosis. Prog Mol Biol Transl Sci 2010;93:309–34
   PubMed Web of Science ®Google Scholar
• Wall JS, Richey T, Williams A, Stuckey A, Osborne D, Martin E, Kennel SJ. Comparative analysis of peptide p5 and serum amyloid P component for imaging AA amyloid in mice using dual-isotope SPECT. Mol Imaging Biol. 2012;14:402–7
   PubMed Web of Science ®Google Scholar
• Solomon A, Weiss DT, Schell M, Hrncic R, Murphy CL, Wall J, McGavin MD, et al. Transgenic mouse model of AA amyloidosis. Am J Pathol 1999;154:1267–72
   PubMed Web of Science ®Google Scholar
• Wall JS, Richey T, Allen A, Donnell R, Kennel SJ, Solomon A. Quantitative tomography of early-onset spontaneous AA amyloidosis in interleukin 6 transgenic mice. Comp Med 2008;58:542–50
   PubMed Web of Science ®Google Scholar
• Ailles L, Kisilevsky R, Young ID. Induction of perlecan gene expression precedes amyloid formation during experimental murine AA amyloidogenesis. Lab Invest 1993;69:443–8
   PubMed Web of Science ®Google Scholar
• Axelrad MA, Kisilevsky R, Willmer J, Chen SJ, Skinner M. Further characterization of amyloid-enhancing factor. Lab Invest 1982;47:139–46
   PubMed Web of Science ®Google Scholar
• Wall JS, Paulus MJ, GLeason S, Gregor J, Solomon A, Kennel SJ. Micro-imaging of Amyloid in Mice. Meth Enzymol 2006;412:161–82
   PubMed Web of Science ®Google Scholar
• Villemagne VL, Rowe CC. Amyloid imaging. Int Psychogeriatr 2011;23:S41–9
   Google Scholar
• Mathis CA, Mason NS, Lopresti BJ, Klunk WE. Development of positron emission tomography beta-amyloid plaque imaging agents. Semin Nucl Med 2012;42:423–32
   PubMed Web of Science ®Google Scholar
• Kung MP, Weng CC, Lin KJ, Hsiao IT, Yen TC, Wey SP. Amyloid plaque imaging from IMPY/SPECT to AV-45/PET. Chang Gung Med J 2012;35:211–8
   Google Scholar
• Doraiswamy PM, Sperling RA, Coleman RE, Johnson KA, Reiman EM, Davis MD, Grundman M, et al. Amyloid-beta assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology 2012;79:1636–44
   PubMed Web of Science ®Google Scholar
• Newberg AB, Arnold SE, Wintering N, Rovner BW, Alavi A. Initial clinical comparison of 18F-florbetapir and 18F-FDG PET in patients with Alzheimer disease and controls. J Nucl Med 2012;53:902–7
   Google Scholar
• Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, Pontecorvo MJ, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011;305:275–83
   PubMed Web of Science ®Google Scholar
• Basu S, Kwee TC, Surti S, Akin EA, Yoo D, Alavi A. Fundamentals of PET and PET/CT imaging. Ann N Y Acad Sci 2011;1228:1–18
   PubMed Web of Science ®Google Scholar
• Newkirk KM, Newman SJ, White LA, Rohrbach BW, Ramsay EC. Renal lesions of nondomestic felids. Vet Pathol 2011;48:698–705
   PubMed Web of Science ®Google Scholar
• Chew DJ, DiBartola SP, Boyce JT, Gasper PW. Renal amyloidosis in related Abyssinian cats. J Am Vet Med Assoc 1982;181:139–42
   PubMed Web of Science ®Google Scholar
• Martin E, Kennel S, Richey T, Stuckey A, Osborne D, Wall J. The peptide p5 binds rapidly to vicseral amyloid in vivo and persists for more than 72 h rendering it suitable for PET/CT imaging using I124. J Nuc Med 2012;53:336P
   Google Scholar